Newsletter Tool

Editor's Note: Fierce Biotech will not publish on Thursday or Friday in observance of Independence Day. We'll be back in your inbox on Monday, July 7.

Today’s Big News

Jul 2, 2025

Why 'emboldened' activist investors are taking the fight to biotechs

Organon axes 'biggest potential opportunity' after flunking phase 2 trial

Biokin, having landed BMS deal, posts ph. 3 cancer win for bispecific ADC

Catalio's $400M fund takes advantage of 'historic buyer's market in biotech'

Vyne prunes psoriasis trial under FDA hold, but keeps faith in BET inhibitor

Shionogi puts more than $600M on the table for Swiss biotech's antibiotic program

Federal judge sides with states, partially blocking HHS reorganization and mass layoffs

Featured

Why 'emboldened' activist investors are taking the fight to biotechs

By James Waldron

Whether it’s drug developers being pressured to wind down or investors accused of trying to “strip mine” a biopharma, shareholder meetings are increasingly becoming verbal battlegrounds for beleaguered biotechs.

Organon axes 'biggest potential opportunity' after flunking phase 2 trial

By Nick Paul Taylor

A drug candidate Organon hailed as perhaps its “biggest potential opportunity” has flunked a phase 2 trial, prompting the company to end clinical development of the endometriosis prospect.

Biokin, having landed BMS deal, posts ph. 3 cancer win for bispecific ADC

By Nick Paul Taylor

A phase 3 trial of Biokin’s bispecific antibody-drug conjugate has hit at least one primary endpoint, boosting the prospects of a candidate that Bristol Myers Squibb licensed outside of China for $800 million upfront.

Puerto Rico: The Bioscience Reshoring Powerhouse the Industry Can’t Afford to Miss

Catalio's $400M fund takes advantage of 'historic buyer's market in biotech'

By Gabrielle Masson

Catalio Capital Management has closed its fourth venture fund with more than $400 million that will be used in part to launch two new companies.

Vyne prunes psoriasis trial under FDA hold, but keeps faith in BET inhibitor

By James Waldron

Vyne Therapeutics has given up on hopes of resuming a plaque psoriasis trial of its BET inhibitor placed on hold by the FDA, but the biotech will persevere with the candidate.

Shionogi puts more than $600M on the table for Swiss biotech's antibiotic program

By Darren Incorvaia

Storied Japanese pharma Shionogi is upping its arsenal in the fight against antibiotic resistance. The company is paying 5 million Swiss francs ($6.3 million) upfront for a preclinical antibiotic program from BioVersys on which the two companies will work to turn into clinical candidates.

Federal judge sides with states, partially blocking HHS reorganization and mass layoffs

By Noah Tong

States won a partial block of mass layoffs and the HHS reorganization imposed by the Trump administration in a ruling by a federal district judge Tuesday.

Boehringer backs education drive to improve bronchiectasis management

By Nick Paul Taylor

Boehringer Ingelheim has breathed life into an American Lung Association campaign, providing support for a push to educate people with bronchiectasis about how to better manage the disease.

Sandoz, on a $1.1B investment spree in Slovenia, breaks ground at new $440M biosimilar plant

By Zoey Becker

The latest project, a sterile product manufacturing site in Brnik, will bring Sandoz' total planned and ongoing investments in Slovenia to more than $1.1 billion by 2029.

Senate passes reconciliation bill in 51-50 vote

By Dave Muoio

Following a record-breaking "vote-a-rama" and tie-breaker vote, the massive bill now returns to the House where it is expected to face more scrutiny.

Fierce podcasts

Don’t miss an episode

Rethinking the mental healthcare model

In this episode of "Podnosis," we explore how mental healthcare can evolve into a more connected, whole-person model.

Teva’s CEO shares ‘Pivot to Growth’ progress

AbbVie, ADCs and the future of cancer care

Resources

Whitepaper

How Will US Policy Impact the Growth of UK Biotech?

Presented by Blue Matter, strategic consultants in the life sciences

Specialized Support to Accelerate Biotech Success

Biotech innovation doesn’t slow down—and neither should your lab partner. This brief outlines how early scientific engagement, operational transparency, and integrated global lab services help reduce risk, stay on schedule, and deliver results. Whether you're navigating your first trial or scaling a growing pipeline, see how a purpose-built lab model can help you move smarter and faster.